M ANY STUDIES HAVE shown that thiazolidinediones
(TZDs) produce insulin sensitizing effects in animal models (1) (2) (3) (4) and in insulin-resistant human subjects (5) (6) (7) . It is now clear that TZDs are high affinity ligands for the nuclear receptor, PPAR␥, which can transactivate PPARresponsive gene promoters (8) . Moreover, in vivo efficacy of TZDs in rodents generally correlates with in vitro PPAR␥ activity (2, 9) . We and others have also discovered non-TZD PPAR␥ agonists with efficacy in rodent models of type 2 diabetes (10, 11) . An important recent observation that serves to further validate PPAR␥ as a key controller of insulin sensitivity and glycemia was the finding of dominant-negative PPAR␥ gene mutations in two families with an inherited form of insulin-resistant type 2 diabetes (12) .
Despite a wealth of knowledge pertaining to PPAR␥ functions, mechanism(s) that underlie the ability of PPAR␥ agonists to improve in vivo insulin sensitivity and hyperglycemia are not well understood. After chronic agonist therapy, skeletal muscle glucose disposal is improved (13, 14) ; in addition, insulin-mediated suppression of hepatic glucose output is enhanced (13) (Doebber, T., unpublished). However, it is doubtful that net improvements in whole body glucose homeostasis can be explained by direct actions of PPAR␥ in liver or muscle. In contrast to direct effects of PPAR␥ agonists to augment insulin action in cultured adipose tissue (15) , we were unable to detect direct effects using isolated skeletal muscles from normal or insulin-resistant rodents (14) . In addition, PPAR␥ expression levels in liver are very low (16) , and there is no convincing evidence that PPAR␥ agonists have direct effects on hepatic insulin action. Therefore, we hypothesized that PPAR␥ agonists have predominant direct effects on adipose tissue that result in secondary beneficial effects on muscle and/or liver. The fact that PPAR␥ agonists lower circulating FFAs, presumably via increased FATP1 and FAT/CD36 levels in adipose tissue and possibly a decrease in lipolysis, is consistent with this hypothesis (17) .
Other than changes in circulating FFAs, it is likely that additional effects on adipose tissue could contribute to metabolic efficacy. Among a number of known proteins that are expressed in adipocytes, we recently obtained preliminary data suggesting that adipocyte complement-related protein of 30 kDa (Acrp30) might be a gene that could be modulated by PPAR␥ (18) . Acrp30, also known as adiponectin or AdipoQ, is a fat-specific expressed gene that encodes a secreted protein that circulates in plasma (19) . Importantly, Acrp30 has also been recently implicated as a factor which Abbreviations: Acrp, Adipocyte complement-related protein of 30 kDa; aP2, adipocyte fatty acid binding protein; BMI, body mass index; FATP1, fatty acid transport protein; HFD, high fat diet; TZDs, thiazolidinediones.
can mediate FFA lowering, enhanced in vivo insulin sensitivity and glucose lowering in rodents (18, 20, 21) .
Here, we have systematically analyzed the PPAR␥-mediated induction of Acrp30. Treatment of 3T3-L1 preadipocytes with PPAR␥ agonists induces Acrp30 mRNA expression. White adipose tissue Acrp30 mRNA expression was induced after chronic treatment of diabetic mice with PPAR␥ agonists. Using a polyclonal Acrp30 antibody, we demonstrated that plasma Acrp30 levels from two diabetic mouse models were increased in response to PPAR␥ agonist treatment. As there are currently no existing specific circulating biomarkers of PPAR␥ agonist effects in humans, we sought to determine if plasma Acrp30 protein levels would be affected by treatment of human subjects with a PPAR␥ agonist. After treatment of normal volunteers with rosiglitazone, a significant increase in Acrp30 levels was observed. Finally, we demonstrated for the first time that circulating Acrp30 levels were substantially reduced in patients with dominant-negative PPAR␥ mutations. Our results suggest that induction of Acrp30 may represent a key mechanism that contributes to the beneficial metabolic effects of PPAR␥ agonists and that measurement of Acrp30 levels may prove to be a valuable biomarker that can be used to gauge the extent of in vivo PPAR␥ activation in humans.
Materials and Methods

Culture and treatment of 3T3-L1 preadipocytes
3T3-L1 cells (ATCC, Manassas, VA; passages 3-9) were grown to confluence in medium A (DMEM with 10% FCS, 100 U/ml penicillin, and 100 g/ml streptomycin) at 37 C in 5% CO 2 as previously described (22) . Differentiation was induced by incubating the confluent fibroblasts with medium A supplemented with methylisobutylxanthine, dexamethasone, and insulin for 2 d, followed by another 2-d incubation with medium A supplemented with insulin. The cells were further incubated in medium A for an additional 3 d to complete the adipocyte conversion. RNA samples were prepared from fibroblasts, preadipocytes treated Ϯ indicated ligands in the differentiation medium for 6 or 48 h, or fully differentiated adipocytes in medium A Ϯ ligands for 6 or 48 h.
In vivo animal studies
Male db/db mice (10-to 11-wk-old C57Bl/KFJ, The Jackson Laboratory, Bar Harbor, ME) were housed 7/cage and allowed ad libitum access to ground Purina rodent chow and water. The animals, and their food, were weighed every 3 d and were dosed daily by gavage with vehicle (0.25% carboxymethylcellulose) Ϯ PPAR agonists at the indicated doses. Plasma glucose and triglyceride concentrations were determined from blood obtained by tail bleeds at 3-to 4-d intervals during the studies. Glucose and triglyceride determinations were performed using assay kits with glucose oxidase for glucose (Sigma, St. Louis, MO) and glycerol kinase for triglycerides (Roche Molecular Biochemicals, Indianapolis, IN), respectively. Lean animals were age-matched heterozygous mice maintained in the same manner.
A nongenetic mouse model of diabetes (23) was generated as follows. Four-week-old male ICR mice (Taconic, Germantown, NY) were fed with high fat diet (HFD, 36% w/w, 58.4% kcal%, Research Diets, Inc., New Brunswick, NJ; D00031501) for 3 wk followed by a single ip administration of STZ at 100 mg ϫ kg Ϫ1 BW. Animals were fed HFD for an additional 4 wk. Mice fed regular chow and injected with saline were used as controls. The HFD/STZ mice were treated twice daily with oral gavage of vehicle (0.5% methylcellulose) or vehicle containing compounds. Blood glucose was monitored with a glucometer (OneTouch Basic, Lifescan, Newtown, PA). Other parameters were measured as described above.
Human clinical study protocol
This was a single center, open-labeled, randomized, placebocontrolled, balanced, incomplete block, 4-treatment, 3-period crossover pilot study with the four treatments consisting of placebo, fenofibrate (201 mg once a day), fenofibrate (201 mg once a day) plus rosiglitazone (4 mg bid), and rosiglitazone (4 mg twice daily). The duration of treatment was 14 d, and there was at least a 14-d washout between periods. Each subject participated in three treatment periods in balanced fashion such that nine subjects received each treatment. Plasma for Acrp30 concentration determination was obtained predose on d 1 (baseline) and 2 h after the last dose on d 14 for each period. All 12 subjects were healthy males who varied in age from 18 -42 yr (mean age 24 yr) and in weight from 61-110 kg (mean weight 89 kg). These subjects refrained from all other medication use from 14 d before completion of the trial. They had no evidence or family history of diabetes mellitus, baseline fasting plasma glucose was Ͻ 110 mg/dl and Ͻ 140 mg/dl 2 h after a 75-g oral glucose load, and baseline the baseline fasting plasma lipid profile (including triglycerides and total cholesterol) was within the reference range for the laboratory. All subjects gave written informed consent and the clinical protocol was reviewed by and approved by Schulman Associates Institutional Review Board (Cincinnati, OH). This clinical study was conducted according to the Declaration of Helsinki principles.
The log percent change [i.e. log(post/pre)] in Acrp30 levels was analyzed by using an analysis of covariance model, appropriate for balanced, incomplete block, 4-treatment, 3-period crossover. The final analysis of covariance model contained factors for subject, period, treatment, and baseline Acrp30 level (at the start of each treatment period). To assess the magnitude of the effect between the active treatment groups and placebo, 95% confidence intervals on the least square mean difference for the log percent change from baseline were also computed (24) . All data were back-transformed to the original percent change from baseline scale for presentation purposes. For the purpose of this analysis, no results were available for the combination group of fenofibrate and rosiglitazone treatment group.
Additional plasma samples were obtained from three patients with dominant-negative PPAR␥ mutations, three additional normal control subjects, and eight patients with severe insulin resistance without mutations in the coding region of PPAR␥.
Measurement of mRNA expression
Total RNA was prepared from cells and tissue using the Ultraspec RNA isolation kit (Biotecx, Houston, TX) then DNase treated using DNA-free according to the manufacturer's protocol (Ambion, Inc. Austin, TX). RNA concentrations were quantitated with Ribogreen by following the supplier's directions (Molecular Probes, Inc., Eugene, OR). Expression levels of Acrp30, adipocyte fatty acid binding protein (aP2), and fatty acid transport protein (FATP1) mRNAs were quantified using quantitative fluorescent real time PCR. RNA was first reverse-transcribed using random hexamers in a protocol provided by the manufacturer (PE Applied Biosystems, Foster City, CA). Amplification of each target cDNA was then performed with TaqMan PCR Reagent Kits in the ABI Prism 7700 Sequence Detection System according to the protocols provided by the manufacturer (PE Applied Biosystems). The following primer/probe sets were used for the amplification step:
The levels of mRNA were normalized to the amount of 18S ribosomal RNA (primers and probes commercially available from PE Applied Biosystems) detected in each sample.
Measurement of Acrp30 protein levels in plasma
Acrp30 was measured by quantitative Western blotting. After SDS-PAGE, proteins were transferred to BA83 nitrocellulose (Schleicher & Schuell, Inc., Keene, NH). Nitrocellulose membranes were stained with Ponceau S solution to ensure even and complete transfer of all samples and subsequently blocked in PBS or Tris-buffered saline with 0.1% Tween-20 and 5% nonfat dry milk. An affinity-purified rabbit antimouse Acrp30 antibody raised against a peptide comprising the hypervariable region (EDDVTTTEELAPALV) was used (19) ; this antibody recognizes a single band by Western blot analysis that can effectively be competed with excess immune peptide. This antibody was derivatized with 125 I and was used to decorate the blots. Each gel contained four standards of purified mouse Acrp30 at four different concentrations to ensure linearity and reproducibility of the signal. For the analysis of human serum samples, a rabbit antihuman Acrp30 antibody, directed against the hypervariable region of the human protein (DQETTTQGPGV), was employed. This antibody was visualized with an 125 I-derivatized secondary goat antirabbit antibody; a standardized human serum sample was also applied to each gel in four different concentrations. However, as no standard for recombinant human Acrp30 protein was included, human plasma levels are expressed as relative units/ml rather than as absolute values. Blots were analyzed with a PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA) and quantitated with ImageQuant software (Molecular Dynamics, Inc.). Intraassay variability was measured using the same serum sample with two replicates per blot, with standards, and quantitating the se of the two measurements; the se was 9%.
Interassay variability based on the measurement of serum samples from the same experiment assayed at different times gave a sem of 10 -20%, emphasizing the high level of reproducibility of the assay. Lower limits of detection are 1-5 ng of Acrp30 protein. For protein extractions from adipose tissue and liver, 100 mg of tissue was mixed with 1 ml of ice-cold Tris-buffered saline containing protease inhibitors, sonicated for 10 sec, and centrifuged at 13,000 ϫ g for 2 min. The fat cake was removed by suction, Triton X-100 was added to the infranatant to a final concentration of 1%, samples sonicated again for 10 sec, centrifuged at 13,000 ϫ g, and the supernatant used for protein determinations by BCA (Pierce Chemical Co., Rockford, IL).
Results
PPAR␥ agonists mediate induction of Acrp30 gene expression in 3T3-L1 preadipocytes
To assess the effects of PPAR␥ activation on Acrp30 gene expression in 3T3-L1 cells, we employed two previously described compounds (10) oxazoly)-2-hydroxyethoxy]benzyl-2,4-thiazolidinedione, and a potent non-TZD, L-796449 (nTZD1). 3T3-L1 preadipocytes were incubated with 1 m of TZD1 or nTZD1 vs. control medium for 6 h or 48 h. As depicted in Fig. 1A , Acrp30 mRNA was rapidly induced (ϳ10ϫ) during the first 48 h of differentiation and both PPAR␥ agonists produced a marked (ϳ5-fold) further increase at the 48-h time point. Both compounds resulted in a similar increase in the expression of a well characterized PPAR␥ target gene, aP2 (Fig. 1C) .
In fully differentiated 3T3-L1 adipocytes, the Acrp30 mRNA levels were induced by more than 1,000-fold compared with the level in undifferentiated fibroblasts. In contrast to the effects of PPAR␥ agonists on Acrp30 in preadipocytes, TZD1 and nTZD1 did not alter Acrp30 mRNA levels further in differentiated adipocytes (Fig. 1B) . In comparison, aP2 mRNA levels were increased by approximately 100-fold in adipocytes relative to fibroblasts and treatment of adipocytes with TZD1 and nTZD1 resulted in further elevations of aP2 mRNA level (ϳ2-fold at 6 h, ϳ4-fold at 48 h).
Effects of in vivo PPAR␥ agonist treatment on Acrp30 gene expression in white adipose tissue and plasma Acrp30 levels in db/db mice
Male db/db mice with overt hyperglycemia (mean plasma glucose levels Ͼ 600 mg/dl) were treated with rosiglitazone at a dose of 10 mg/kg⅐d via daily oral gavage. Following 11 d of treatment, samples of white adipose tissue (epididymal) and plasma were obtained (24 h after the last dose of rosiglitazone). Table 1 shows d-11 values for glucose, triglycerides, and body weight in rosiglitazone-treated mice vs. db/db mice treated only with vehicle and lean control mice. Rosiglitazone treatment was associated with 50% reduction in glycemia and reduced triglyceride levels below those observed in lean db/ϩ mice. Body weights increased with rosiglitazone treatment by approximately 10%.
Measurement of adipose tissue Acrp30 mRNA by quantitative RT-PCR revealed that Acrp30 mRNA levels in vehicle-treated db/db control mice were approximately 50% lower than in lean control mice ( Fig. 2A) . Rosiglitazone treatment of db/db mice was associated with a significant (vs. vehicle) increase in mean Acrp30 mRNA levels. Thus, TZD treatment resulted in levels of adipose Acrp30 mRNA that approached levels in lean mice. As a control, we also examined the effect of rosiglitazone treatment on expression of FATP1, a fatty acid transport protein that is known to be a direct PPAR␥ target gene (17) . Similar to Acrp30, FATP1 mRNA levels were significantly induced in adipose tissue following in vivo TZD treatment. (Fig. 2B) . Similar results were obtained in three independent db/db mouse studies.
To assess the effects of in vivo rosiglitazone treatment on circulating plasma levels of Acrp30, we developed a quantitative immunoblot method using a polyclonal Acrp30 antibody. To illustrate linearity of the Western blot method, increasing amounts of HEK293-T produced and purified Acrp30 (18) were analyzed by quantitative immunoblotting (Fig. 3A) . Each SDS-PAGE gel contained a similar set of four standards to allow quantitative comparison of samples on separate gels. The linearity of the signal was also tested using incremental increases in serum sample amount (not shown). Plasma samples from two separate db/db mouse studies were analyzed. As depicted in Fig. 3B , mean Acrp30 levels in db/db mice increased by approximately 3-to 4-fold after TZD1 or rosiglitazone treatment vs. vehicle. Treatment with a PPAR␣ agonist, fenofibrate (150 mg/kg⅐d), did not lower glucose or induce an increase in Acrp30 levels (Fig. 3B ) despite a significant (27%) decline in mean triglyceride levels (not shown). To determine whether the elevation of circulating Acrp30 levels precedes, coincides with, or follows the decrease in serum glucose levels, a more detailed time-course study was performed. Rosiglitazone or vehicle treatment was administered daily to db/db mice for a period of 11 d (Fig. 3C) . During that period, serum glucose and Acrp30 levels were measured at several intervals. Serial blood samples were also obtained from a parallel group of lean db/ϩ control mice. In vehicle-treated db/db mice and in untreated lean mice, serum Acrp30 and glucose levels remained unchanged. On fourth and subsequent days of dosing with rosiglitazone, plasma glucose levels were significantly decreased (P Ͻ (Ͼ3-fold increase) . Acrp30 levels continued to increase linearly throughout the 11-d regimen resulting in 6-fold elevation by the end of the study compared with initial levels. These results indicate that increased serum Acrp30 levels may precede (or at least coincide with) correction of hyperglycemia in this insulin-resistant murine model.
To confirm that rosiglitazone treatment leads to an upregulation of Acrp30 protein within various fat pads, protein was extracted from epididymal, abdominal, interscapular white, and interscapular brown adipose tissue as well as liver from both vehicle-and rosiglitazone-treated animals at the end of the experiment. Protein extracts were analyzed by SDS-PAGE and quantitative immunoblotting for Acrp30 (Fig. 3E ). Epididymal and abdominal pads responded to rosiglitazone treatment with a marked increase of Acrp30, suggesting that a significant fraction of the increase in serum Acrp30 levels is caused by increased production. Decreased clearance of serum Acrp30 therefore cannot exclusively account for the increase in circulating Acrp30. As expected, the liver (not perfused) did not have significant amounts of Acrp30, even after rosiglitazone treatment. Surprisingly, production of Acrp30 in interscapular white and brown adipose tissue was not affected by rosiglitazone treatment, suggesting a fat depot specific response to rosiglitazone action.
PPAR␥ agonist-mediated induction of Acrp30 plasma levels in a nongenetic rodent model of type 2 diabetes
Additional in vivo experiments were conducted using a nongenetic model of type 2 diabetes. Combined low-dose streptozotocin treatment and high-fat feeding (HFD/STZ) of ICR mice resulted in moderate hyperglycemia vs. control ICR mice on a normal chow diet (see Table 2 ). Twice daily oral gavage treatment of HFD/STZ mice for 11 d with 10 mg/kg doses of rosiglitazone or an additional potent PPAR␥ selective non-TZD compound, L-805645 (nTZD2) (25) resulted in substantial correction of hyperglycemia (Table 2 ). In addition, a separate group of HFD/STZ mice received metformin (at a dose of 200 mg/kg given twice daily) as an alternative antidiabetic therapy that is known to be independent of PPAR␥ activity. Treatment with both PPAR␥ agonists and metformin resulted in significant reduction in hyperglycemia. Plasma samples were obtained on d 11 and subsequently analyzed for determination of Acrp30 protein levels. As depicted in Fig. 4 , mean Acrp30 levels were substantially increased by treatment with either the TZD or non TZD PPAR␥ agonist. In contrast, metformin had no effect on mean Acrp30 plasma levels.
Treatment of human subjects with rosiglitazone results in the induction of mean plasma Acrp30 levels
Healthy male subjects were treated with rosiglitazone at a dose of 4 mg orally twice daily for 14 d. Similarly, these subjects were treated orally with placebo once daily for 14 d, fenofibrate 201 mg orally once daily, and the combination of rosiglitazone and fenofibrate (not assessed in this study). As shown in Fig. 5 , rosiglitazone treatment for 14 d produced an approximately 130% least square mean increase from baseline in circulating Acrp30 levels vs. placebo (statistically significant at P ϭ 0.010). In contrast, fenofibrate treatment had no significant effect on mean Acrp30 levels.
Patients with dominant-negative PPAR␥ mutations have suppressed Acrp30 levels
We previously reported two dominant-negative PPAR␥ mutations (Val 290 -Met and Pro 467 -Leu) that occurred in association with severe insulin resistance and type 2 diabetes (12). Plasma Acrp30 levels were measured in two probands with the Pro 467 -Leu allele and in one with the Val 290 -Met allele (12) . As shown in Table 3 , Acrp30 levels in these patients were within a very low range (0.17-0.71 U/ml) compared with values measured at the same time in three unrelated normal control subjects and compared with placebo or pretreatment values measured in the experiments described for normal human subjects in Fig. 5 . In addition, mean values from the three probands with dominantnegative mutations were significantly lower (5-fold) than the mean of values measured with samples from 8 unrelated patients with severe insulin resistance in whom no mutations in the PPAR␥ coding region were detected (a subset of the 85 patients studied in Ref. 12 ). Furthermore, the plasma Acrp30 level remained below "normal" following 12 wk of treatment of the Val 290 -Met patient with rosiglitazone (Table 3) . This is consistent with the fact that this mutation renders the receptor nearly unresponsive to activation by rosiglitazone in vitro (12) . Although body mass index (BMI) values tended to be lower in the three probands than in the other study subjects, there was no significant correlation between Acrp30 and BMI in the larger cohort of insulin resistant patients (subjects 7-14 in Table 3 ). Not every decrease of Acrp30 levels in diabetic patients is caused by a mutation in PPAR␥ because a number of epidemiological studies have reported a decrease in parallel with reduced insulin sensitivity during the progression to type 2 diabetes (26, 27) . Some of patients 7-14 will most likely display decreased Acrp30 levels for reasons unrelated to mutations in PPAR␥. In summary, upon ranking circulating Acrp30 levels of all these patients, it is striking that all three patients with known mutations interfering with PPAR␥ activity display the lowest serum Acrp30 levels.
Discussion
The cDNA encoding a novel protein, adipocyte complement-related protein of 30 kDa (Acrp30), was initially identified by subtractive cloning or mRNA differential display from cultured adipocytes vs. preadipocytes (19, 28) . Acrp30 is a protein of 247 amino acids that bears homology to complement factor C1q; it contains both an amino-terminal collagenous domain and a C-terminal globular domain. Interestingly, the x-ray crystal structure of the globular domain shows it to be similar to that of TNF␣ (29) . The distribution of Acrp30 mRNA in mouse, rat, and human is confined almost exclusively to adipose tissue and its expression is strongly induced during differentiation of cultured preadipocytes (3T3-L1 or 3T3-F442A) mediated by a cocktail containing dexamethasone, isobutylmethylxanthine, and insulin (19, 28) . Hu et al. (28) also showed that Acrp30 mRNA expression levels were reduced in white adipose tissue derived from obese mice (ob/ob) or humans vs. fat tissue from lean controls. Importantly, Acrp30 is a secreted protein that circulates in plasma at high concentrations (5-10 g/ml) (19). These observations suggested that Acrp30 represents a circulating adipose-derived factor, like leptin, which could influence energy balance and/or metabolic perturbations that are associated with obesity. Several recent reports have functionally linked Acrp30 to improved systemic insulin sensitivity (18, 20, 21) . Lodish and colleagues (20) reported that acute administration of recombinant Acrp30 lowered postprandial levels of glucose, triglycerides, and FFAs in mice fed with high-fat and sucrose. Greater efficacy was seen with a truncated 27-kDa version of the protein containing the globular head domain than with the full-length protein; however, 5 . Treatment of healthy human subjects with rosiglitazone produces a significant increase from baseline in mean Acrp30 plasma levels (P ϭ 0.010 vs. placebo change from baseline). Effects of placebo, rosiglitazone (4 mg twice daily), or fenofibrate (201 mg once daily) on plasma Acrp30 levels in healthy male subjects (n ϭ 8, placebo; n ϭ 9, rosiglitazone and fenofibrate treatments). Acrp30 plasma levels were determined using plasma samples obtained predose on d 1 (closed circles) and 2 h after the last study drug dose on d 14 of treatment (open circles). Mean Ϯ SEM values are depicted.
postprandial glucose levels were similarly affected by both forms of Acrp30 in this experimental paradigm. In addition, an effect of the 27-kDa protein to induce fatty acid oxidation in cultured skeletal muscle cells was described. In line with these observations, Kadowaki and colleagues (21) showed that Acrp30 leads to the increased expression of molecules involved in fatty acid oxidation and energy dissipation in muscle and were able to reverse insulin resistance in lipoatrophic mice only upon combined administration of Acrp30 and leptin. We have recently observed that single injections of full-length Acrp30 produced lowered glucose levels in both normal, ob/ob mice and NOD mice, independently of an increase in insulin levels (18) . The fact that recombinant Acrp30 could also enhance the effect of insulin to suppress glucose output from cultured hepatocytes suggests that a primary effect of this protein may be to augment hepatic insulin action.
A study by Tataranni and colleagues (26) in Caucasians and Pima Indians (a population with a high propensity for obesity and type 2 diabetes) further corroborates the relationship with metabolic parameters. After multivariate analysis, the authors concluded that decreased plasma Acrp30 levels ("hypoadiponectinemia") are more closely related to the degree of insulin resistance and hyperinsulinemia than to the degree of adiposity and glucose intolerance. Furthermore, Comuzzie et al. (30) have found that the Acrp30 gene locus (3q27) demonstrates significant LOD scores influencing phenotypic aspects of metabolic syndrome X.
In the present studies, we sought to further explore whether Acrp30 mRNA or protein levels could be affected by PPAR␥ activation, and how the Acrp30 induction is kinetically related to the TZD-mediated reduction of serum glucose levels. We initially determined that PPAR␥ agonists strongly induced Acrp30 mRNA expression in cultured 3T3-L1 preadipocytes. As similar results were obtained using both a TZD and a non-TZD PPAR␥ ligand and because stimulation of Acrp30 was observed with concentrations of these compounds that were within a 10-fold range of their respective PPAR␥ binding affinities, it is apparent that PPAR␥ activation per se was sufficient to produce this effect (along with other aspects of adipocyte differentiation). The question whether Acrp30 is a gene that is directly transactivated by PPAR␥ via a PPAR␥-responsive elements in its promoter remains an important one. We previously cloned and sequenced the murine Acrp30 promoter region (31) . In several kilobase pairs of this region and in the first intron, there are no consensus PPAR␥-responsive elements sites. Potential sites for CCAAT/enhancer binding protein ␤ (C/EBP␤) suggest a potential mechanism for induction of Acrp30 during adipocyte differentiation and/or as a secondary mechanism by which PPAR␥ might induce Acrp30 gene expression. In agreement with the latter hypothesis, TZDs failed to further induce Acrp30 in isolated, mature 3T3-L1 adipocytes. However, the studies presented here are not focused on this question and do not allow us to conclusively resolve this issue. Rather, we focused on the hypothesis that circulating Acrp30 levels might be modulated in relation to in vivo PPAR␥ activation.
The mechanism(s) by which PPAR␥ activation leads to an increase in circulating Acrp30 levels may therefore include the following: 1) as discussed above, Acrp30 may be a directly affected PPAR␥ target gene; 2) activation of PPAR␥ in vivo is likely to promote an increase in adipogenesis (32) that may result in a greater net capacity for Acrp30 production; 3) posttranslational mechanisms may include the fact that insulin can promote Acrp30 exocytosis in a PI3K-dependent fashion (33) because we and others have shown that PPAR␥ agonists can selectively augment insulin-mediated PI3K ac- Acrp30 levels were determined using plasma samples obtained from three subjects (1-3) with severe insulin resistance (IR) and PPAR␥ dominant-negative mutations. A second sample from subject 3(A) was obtained after chronic therapy (12 wk) with rosiglitazone. Samples from three additional control subjects (4 -6) and from eight patients with severe insulin resistance known to have no mutations within the PPAR␥ coding region (7) (8) (9) (10) (11) (12) (13) (14) were also used. BMI values for each subject are shown. Individual and mean (Ϯ SEM) Acrp30 values are shown.
a , P ϭ 0.02 vs. mean of samples 4 -6; b , P ϭ 0.04 vs. mean of samples 7-14 (one-tailed t test).
tivity (34) . However, both the magnitude of the induction as well as the observation that elevated levels are sustained during the treatment suggests that a purely posttranslational mechanism is unlikely. The rapid induction of Acrp30 levels after initiation of TZD treatment also suggests that an increase in the number of new adipocytes could not fully account for this phenomenon, at least not at the early timepoints of treatment. Furthermore, increased adiposity generally does not lead to an increase in Acrp30 levels in serum (18, 35) ; 4) lastly, the net increase in serum Acrp30 levels could be caused by decreased clearance. While we cannot eliminate a net contribution of decreased clearance, the increased presence of Acrp30 in fat pads suggests a net increase in Acrp30 protein production. Administration of fenofibrate (to db/db mice), a PPAR␣-selective agonist, did not produce an increase in Acrp30 levels despite a significant effect to suppress elevated triglycerides. More importantly, treatment of HFD/STZ mice with a non-PPAR-associated antihyperglycemic agent, metformin, produced significant efficacy without affecting mean Acrp30 levels. These observations have very important implications for our understanding of the regulation of Acrp30 expression. They demonstrate that the effect of insulin sensitizers on in vivo Acrp30 levels is indeed (directly or indirectly) PPAR␥ mediated, and that changes in Acrp30 are not simply a consequence of an improved metabolic phenotype.
In agreement with the observations reported in this paper, Matsuzawa and colleagues (36) recently reported that the administration of TZDs significantly increased the plasma adiponectin (also known as Acrp30) concentrations in insulinresistant humans and rodents. They demonstrated that adiponectin mRNA expression was normalized or increased by TZDs in the adipose tissues of obese mice. However, in contrast to our observations, they showed that cultured 3T3-L1 adipocytes enhanced the mRNA expression and secretion of adiponectin in a dose-and time-dependent manner in response to TZDs. We cannot fully explain these differences, but a likely explanation lies in the use of different clonal isolates of 3T3-L1 cells that may differ with respect to their ability to induce the factor(s) that critically mediate the TZD-induced transcriptional changes with respect to Acrp30 induction.
At present, there are no known human biomarkers that are specific for in vivo activation of PPAR␥ as well as useful in healthy volunteers or patients with type 2 diabetes. In patients with type 2 diabetes, measures of glucose metabolism are useful surrogates, but these measures are not specific to activation of PPAR␥. Such biomarkers of activation of PPAR␥, if affected in a short time-frame, would be invaluable in helping to determine whether individual patients are responding to treatment with PPAR␥ agonists and in aiding in the quantitation of in vivo PPAR␥ tone as a potential contributor to specific metabolic disease states. A key finding of the present study is the clear effect of in vivo treatment with a therapeutic dose of rosiglitazone to significantly increase mean Acrp30 levels in a placebo-controlled trial with normal human subjects. It is important to note that other metabolic parameters such as insulin, glucose, and FFAs were not affected in a statistically significant fashion by rosiglitazone in these otherwise healthy, normal volunteers (data not shown). In addition, such metabolic effects of rosiglitazone and related TZD PPAR␥ agonists that have been previously reported to occur in patients with type 2 diabetes typically occur more gradually, over the course of 6 -12 wk (7, 37). As part of this exploratory clinical trial, subjects also received treatment with a therapeutic dose of fenofibrate. As we observed in mice, fenofibrate did not affect circulating Acrp30 levels in humans. Given these observations, it is apparent that increased Acrp30 is a robust, relatively early, specific response to activation of PPAR␥ in humans. A detailed human time course experiment is necessary to demonstrate that Acrp30 increases precede overt changes in the in vivo metabolic milieu, although the time course results in db/db mice are suggestive (see Fig. 3 ). Acrp30 represents a novel and potentially important biomarker for PPAR␥ activation. Further studies are required to determine whether PPAR␥-mediated effects on Acrp30 occur in patients with type 2 diabetes, assess whether improvements in insulin sensitivity correlate with Acrp30 induction, and define a PPAR␥ agonist dose-response relationship for Acrp30.
The Pro 467 -Leu or Val 290 -Met PPAR␥ mutations are known to encode receptors with severely reduced function and dominant-negative properties in vitro (12) . Thus, our observation that circulating Acrp30 levels were suppressed in severely insulin-resistant patients with either of these mutant alleles provides strong evidence that normal physiologic degrees of PPAR␥ activation regulate Acrp30 levels in humans. The role of PPAR␥ in mediating the effect of rosiglitazone to induce Acrp30 in vivo in humans was also bolstered by finding that chronic rosiglitazone treatment failed to substantially induce Acrp30 in a patient with the Val 290 -Met mutation. The recent reports cited above that demonstrate that Acrp30 can modulate systemic insulin sensitivity support the hypothesis that PPAR␥ agonists mediate an increase in circulating Acrp30 protein levels that, in turn, produces effects on liver and muscle that may act in concert to cause several of the well described net in vivo effects of TZDs: hepatic insulin sensitization, glucose lowering, FFA lowering, and (at least in rodents) triglyceride lowering. Given that suppressed Acrp30 levels were observed in patients with dominant-negative PPAR␥ mutations, it is also tempting to speculate Acrp30 deficiency has an important role in the pathogenesis of severe insulin resistance and type 2 diabetes that is present in these same patients.
